Global Vaccine Adjuvants Market – Industry Trends and Forecast to 2030

Inhaltsverzeichnis anfordernInhaltsverzeichnis anfordern Mit Analyst sprechen Mit Analyst sprechen Jetzt kaufenJetzt kaufen Vor dem Kauf anfragen Vorher anfragen Kostenloser Beispielbericht Kostenloser Beispielbericht

Global Vaccine Adjuvants Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Reports
  • Aug 2023
  • Global
  • 350 Seiten
  • Anzahl der Tabellen: 60
  • Anzahl der Abbildungen: 220

Global Vaccine Adjuvants Market

Marktgröße in Milliarden USD

CAGR :  % Diagram

Diagramm Prognosezeitraum
2023 –2030
Diagramm Marktgröße (Basisjahr)
USD 1,350.60 Million
Diagramm Marktgröße (Prognosejahr)
USD 2,950.57 Million
Diagramm CAGR
%
Diagramm Wichtige Marktteilnehmer
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Abbott
  • 3M

Global Vaccine Adjuvants Market, By Product Type (Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants, Liposome Adjuvants, Carbohydrate Adjuvants, Alum, and Others), Route of Administration (Intramuscular Route, Subcutaneous Route, Intranasal Route, Oral Route, Intradermal Route, and Others), Disease Type (Infectious Diseases, Cancer and Others), Application (Research Application and Commercial Application), Application Category (Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants), End-User (Pediatric, Adults, and Others) – Industry Trends and Forecast to 2030.

Vaccine Adjuvants Market

Vaccine Adjuvants Market Analysis and Size

The global vaccine adjuvants market is expected to experience significant growth in the coming years. Factors such as the increasing prevalence of Infectious Disease, expanding vaccination programs, and advancements in adjuvant development are driving market expansion. Additionally, the growing focus on developing vaccines for emerging diseases and the need for improved vaccine efficacy and safety further contribute to market growth.                                

Data Bridge Market Research analyses that the global vaccine adjuvants market which was USD 1,350.6 million in 2022, would rocket up to USD 2,950.57 million by 2030, and is expected to undergo a CAGR of 13.37% during the forecast period. This indicates that the market value. “Infectious” is expected to dominate the disease type segment of the vaccine adjuvants market owing to the growing demand for vaccines for infectious diseases. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Vaccine Adjuvants Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Product Type (Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants, Liposome Adjuvants, Carbohydrate Adjuvants, Alum, and Others), Route of Administration (Intramuscular Route, Subcutaneous Route, Intranasal Route, Oral Route, Intradermal Route, and Others), Disease Type (Infectious Diseases, Cancer and Others), Application (Research Application and Commercial Application), Application Category (Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants), End-User (Pediatric, Adults, and Others)

Countries Covered

U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa

Market Players Covered

Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Astrazeneca (U.K.), Abbott (U.S.), 3M (U.S.), Adjuvatis (France), Merck KGaA (Germany), Croda International Plc (U.K.), Novavax, Inc. (U.S.), InvivoGen (France), CSL Limited, SPI Pharma(U.S.), Phibro Animal Health Corporation. (U.S.), SEPPIC (France), Agenus Inc. (U.S.), OZ Biosciences (France), Kineta, Inc. (U.S.), vaxine (Australia), Astellas Pharma Inc. (Japan), CureVac AG (Germany) and Bavarian Nordic (Denmark)

Market Opportunities

  • Advancements in adjuvant technologies
  • Increasing number of healthcare and pharmaceutical facilities globally
  • Rising research and development opportunities

Market Definition

Vaccine adjuvants are the compounds that are consumed to enhance the body’s immunogenic response against antigens.  The vaccine adjuvants are used for a wide range of applications.

Global Vaccine Adjuvants Market Dynamics

Drivers

  • Increasing Global Disease Burden

The rising prevalence of infectious diseases and the emergence of new pathogens continue to pose significant healthcare challenges globally. This drives the demand for effective vaccines and, in turn, vaccine adjuvants. The need for improved vaccine efficacy and the ability to provide protection against a broader range of pathogens are driving the development and use of adjuvant vaccines.

  • Expansion of Vaccination Programs

Governments and healthcare organizations worldwide are actively expanding vaccination programs to prevent the spread of infectious diseases. This includes routine immunization, national immunization campaigns, and vaccination initiatives in response to epidemics or pandemics. The demand for adjuvants arises from the need to enhance the immune response and improve the effectiveness of vaccines used in these programs.

  • Growing Focus on Preventive Healthcare

There is an increasing emphasis on preventive healthcare measures, including vaccination, to reduce the burden of infectious diseases. The recognition of the cost-effectiveness and public health benefits of vaccines has led to a greater focus on immunization programs. Vaccine adjuvants play a crucial role in enhancing the efficacy of vaccines and achieving the desired immune response, thereby supporting the growth of the market.

  • Growing Investment for Healthcare Facilities

Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

  • Technological Advancements in Vaccine Manufacturing

The advancement of vaccine manufacturing technologies, such as cell culture-based and recombinant DNA technologies, has enabled the production of more complex and targeted vaccines. Adjuvants play a critical role in optimizing these advanced vaccine formulations and improving their immunogenicity. As the vaccine manufacturing landscape evolves, the demand for adjuvants that can complement and enhance these technologies is expected to increase.

  • Advancements in Adjuvant Technologies

The field of adjuvant research and development is continuously advancing, leading to the discovery and development of new and improved adjuvant technologies. Novel adjuvants offer enhanced safety profiles, improved immune responses, and better compatibility with vaccine formulations. The development of innovative adjuvant platforms drives the market by enabling the creation of more effective and tailored vaccines.

Restraints

  • Stringent Regulatory Requirements

Vaccine adjuvants are subject to rigorous regulatory scrutiny due to their direct involvement in the immune response and safety considerations. The regulatory approval process for adjuvant vaccines can be complex and time-consuming. Stringent regulatory requirements may pose challenges for companies developing and commercializing vaccine adjuvants, leading to delays in market entry and increased costs.

  • Safety Concerns and Public Perception

Safety concerns surrounding adjuvant vaccines can impact market acceptance. Although adjuvants are generally considered safe, rare adverse events or public controversies related to vaccine safety can erode public trust and confidence in adjuvant vaccines. Communicating the safety profile and benefits of adjuvant vaccines effectively to the public is crucial for market adoption.

Challenges

  • Regulatory Hurdles and Approval Processes

Vaccine adjuvants are subject to stringent regulatory requirements, and gaining regulatory approval can be a significant challenge. Adjuvants are considered an integral part of the vaccine formulation, and their safety, efficacy, and stability must be thoroughly evaluated. The regulatory process often involves extensive preclinical and clinical studies, which can be time-consuming and costly. Navigating the complex regulatory landscape and meeting the requirements pose challenges for companies developing and commercializing vaccine adjuvants.

  • Cost and Affordability

Vaccine adjuvants can contribute to the overall cost of vaccine development and production. The cost-effectiveness of adjuvants, especially when combined with the cost of adjuvant vaccine production, can be a challenge. Balancing the need for improved vaccine efficacy and immune response with the cost implications is a critical consideration for both manufacturers and healthcare systems. Developing cost-effective adjuvants and optimizing manufacturing processes to reduce production costs are ongoing challenges in the market.

This vaccine adjuvants market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the vaccine adjuvants market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

  • In April 2022, GSK and SK Bioscience submitted a biologics license application to the Korean Ministry of Food and Drug Safety (KMFDS) for their SKYCovione following positive Phase III clinical data. It is a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s pandemic adjuvant
  • In February 2022, Sanofi and GSK intended to submit data from their booster and Phase 3 efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.

Global Vaccine Adjuvants Market Scope

The vaccine adjuvants market is segmented on the basis of product type, route of administration, disease type, application, application category, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

  • Particulate adjuvants
  • Adjuvant emulsions
  • Pathogen components
  • Combination adjuvants
  • Liposome adjuvants
  • Carbohydrate adjuvants
  • Alum
  • Others

Route of Administration

  • Intramuscular route
  • Subcutaneous route
  • Intranasal route
  • Oral route
  • Intradermal route
  • Others

Disease Type

  • Infectious diseases
  • Cancer
  • Others

Application

  • Research application
  • Commercial application

Application Category

  • Human vaccine adjuvants
  • Veterinary vaccine adjuvants

End-User

  • Pediatric
  • Adults
  • Others

Vaccine Adjuvants Market Regional Analysis/Insights

The vaccine adjuvants market is analysed and market size insights and trends are provided by country, product type, route of administration, disease type, application, application category, and end-user as referenced above.

The countries covered in the vaccine adjuvants market report are U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of the Middle East and Africa.

North America is expected to dominate the vaccine adjuvants market owing to the well-established veterinary healthcare infrastructure.   

Asia-Pacific is projected to score the highest growth rate and exhibit the highest CAGR for the forecast period. This is because of the rising expenditure to develop veterinary healthcare infrastructure and the increased focus of the government on immunization programs.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The vaccine adjuvants market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for the vaccine adjuvants market, impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the vaccine adjuvants market. The data is available for the historic period 2015-2020.

Competitive Landscape and Vaccine Adjuvants Market Share Analysis

The vaccine adjuvants market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the vaccine adjuvants market.

Some of the major players operating in the vaccine adjuvants market are:

  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Astrazeneca (U.K.)
  • Abbott (U.S.)
  • 3M (U.S.)
  • Adjuvatis (France)
  • Merck KGaA (Germany)
  • Croda International Plc (U.K.)
  • Novavax, Inc. (U.S.)
  • InvivoGen (France)
  • CSL Limited (Australia)
  • SPI Pharma(U.S.)
  • Phibro Animal Health Corporation. (U.S.)
  • SEPPIC (France)
  • Agenus Inc. (U.S.)
  • OZ Biosciences (France)
  • Kineta, Inc. (U.S.)
  • vaxine (Australia)
  • Astellas Pharma Inc. (Japan)
  • CureVac AG (Germany)
  • Bavarian Nordic (Denmark)


SKU-

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

  • Interaktives Datenanalyse-Dashboard
  • Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
  • Zugriff für Research-Analysten für Anpassungen und Abfragen
  • Konkurrenzanalyse mit interaktivem Dashboard
  • Aktuelle Nachrichten, Updates und Trendanalyse
  • Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Demo anfordern

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

The market is segmented based on , By Product Type (Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants, Liposome Adjuvants, Carbohydrate Adjuvants, Alum, and Others), Route of Administration (Intramuscular Route, Subcutaneous Route, Intranasal Route, Oral Route, Intradermal Route, and Others), Disease Type (Infectious Diseases, Cancer and Others), Application (Research Application and Commercial Application), Application Category (Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants), End-User (Pediatric, Adults, and Others) – Industry Trends and Forecast to 2030. .
The Global Vaccine Adjuvants Market size was valued at USD 1350.60 USD Million in 2022.
The Global Vaccine Adjuvants Market is projected to grow at a CAGR of 13.37% during the forecast period of 2023 to 2030.
The major players operating in the market include Pfizer, GlaxoSmithKline, AstraZeneca, Abbott, 3M, Adjuvatis, Merck KGaA, Croda International, Novavax, InvivoGen, CSL Limited, SPI Pharma, Phibro Animal Health Corporation, SEPPIC, Agenus , OZ Biosciences, Kineta, Vaxine, Astellas Pharma, CureVac AG, Bavarian Nordic.
The market report covers data from the U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa.